August 26, 2024
This article describes PuMP, a clinical trial that aims to evaluate MVR-C5252 — a genetically modified herpes virus designed to selectively attack recurrent high-grade gliomas and stimulate a patient’s immune system to fight the tumor. Delivered directly into the brain tumor via catheter, the trial progresses through multiple stages to assess safety, immune activation, and effectiveness in delaying recurrence and extending survival.
Dr. Khsaraw is a lead investigator in the trial, helping design and implement the multi-phase study protocol. He plays a critical role in administering the treatment, monitoring patient outcomes, and guiding the evaluation of MVR-C5252’s safety, immune effects, and long-term clinical benefits.
Read the full article here.